Marilena Vrana: ”Plasma Powers Possibility” Continues to Resonate Far Beyond an Awareness Week
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”With October now behind us, the IPAW 2025 theme “Plasma Powers Possibility” continues to resonate far beyond an awareness week.
While International Plasma Awareness Week may officially only span the course of a week, its message endures all year long.
Every plasma donation fuels possibility, hope, and opportunity for patients.
Committed, healthy donors are the generous start of a promising future for patients across Europe.
Their generous act of giving allows patients to live healthier, fuller lives.
As patients’ need for plasma-derived medicines continues to grow, we must work together to build resilient systems that support donors and strengthen access for those people whose lives depend on them.
I invite you to read my reflections and share your own on how we can build on the IPAW momentum and continue raising awareness year-round.
Read the full blog post here.”
Stay updated with Hemostasis Today.
-
Mar 11, 2026, 18:27Cesar Garrido and Lackram Bodoe Are Advancing WFH Partnerships in Trinidad and Tobago
-
Mar 11, 2026, 18:14Aloke Finn: Silent Plaque Rupture and Healing in Coronary Artery Disease
-
Mar 11, 2026, 17:23Mattia Galli: A Privilege to Collaborate on Such a Complex Topic as Cardio-Rheumatology
-
Mar 11, 2026, 17:12Shubham Misra: Proteomic Biomarkers for Acute Stroke Subtype Classification
-
Mar 11, 2026, 16:55Melanie Daniel: Modeling High-Purity von Willebrand Factor for Individualized Dosing in Surgery
-
Mar 11, 2026, 15:46Bleeding and Thrombosis Outcomes in Older Patients With Myelodysplastic Syndromes – JTH
-
Mar 11, 2026, 15:37Sonia Muliyil: The Greatest Benefit is The Wellbeing and Sustenance of Half The World’s Population
-
Mar 11, 2026, 15:34Kymentie Ferdinande: Rivaroxaban in Cirrhosis and the Path Toward Individualized Anticoagulation
-
Mar 11, 2026, 15:34Sheharyar Raza: When More Testing Isn’t Always Better in Healthy Donor Screening